Regenerating matrix-based therapy for chronic wound healing: A prospective within-subject pilot study

International Wound Journal

Volumn 8, Issue 1, 2011, Pages 85-95

  Groah, Suzanne L ^a   Libin, Alexander ^a   Spungen, Miriam ^a   Nguyen, Kim Loan ^b   Woods, Earthaleen ^a   Nabili, Marjan ^c   Ramella Roman, Jessica ^c   Barritault, Denis ^d  

^a NATIONAL REHABILITATION HOSPITAL   (United States)

^b VIRGINIA HOSPITAL CENTER   (United States)

^c CATHOLIC UNIVERSITY OF AMERICA   (United States)

^d OTR3 SAS   (France)

Author keywords

Glycosaminoglycans; Heparan sulphate; Wound healing; Wound pain

Indexed keywords

CACIPLIQ20; GLUCOSE POLYMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURN; CLINICAL ARTICLE; CLINICAL TRIAL; DECUBITUS; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; GAUZE DRESSING; HUMAN; MALE; PATIENT SATISFACTION; PILOT STUDY; PRESSURE; PRIORITY JOURNAL; ULCER; VASCULAR LESION; VASCULAR ULCER; VISUAL ANALOG SCALE; WOUND; WOUND HEALING;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; BANDAGES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SULFATASES; TREATMENT OUTCOME; VARICOSE ULCER; WOUND HEALING; YOUNG ADULT;

EID: 78751688180     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/j.1742-481X.2010.00748.x     Document Type: Article

References (72)

1. Armstrong DG, Lavery LA, Wrobel JS, Vileikyte L. Quality of life in healing diabetic wounds: does the end justify the means? J Foot Ankle Surg 2008;47:278-82.
2. Shukla VK, Shukla D, Tripathi AK, Agrawal S, Tiwary SK, Prakash V. Results of a one-day descriptive study of quality of life in patients with chronic wounds. Ostomy Wound Manage 2008;54:43-9.
3. Shukla D, Tripathi AK, Agrawal S, Ansari MA, Rastoqi A, Shukla VK. Pain in acute and chronic wounds: a descriptive study. Ostomy Wound Manage 2005;51:47-51.
4. Whittington KT, Briones R. National prevalence and incidence study: 6-year sequential acute care data. Adv Skin Wound Care 2004;17:490-4.
5. Cuddigan J, Ayello EA, Sussman C, Baranoski S, National Pressure Ulcer Advisory Panel, eds. Pressure ulcers in America: Prevalence, incidence, and implications for the future. Reston, VA. National Pressure Ulcer Advisory Panel. 2001.
6. European Pressure Ulcer Advisory Panel. A European pressure ulcer advisory panel and national pressure ulcer advisory panel collaborative guideline. [accessed on 30 March 2008].
7. Clark M, Bours G, Defloor T. Summary report on prevalence of pressure ulcers. EPUAP Rev 2002;4:49-57.
8. Reifsnyder J, Hoplamazian L. Incidence and prevalence of pressure ulcers in hospice. J Palliat Med 2005;8:244.
9. Tippett AW. Wounds at the end of life. Wounds 2005;17:91-8.
10. Curley MAW, Quigley SM, Lin M. Pressure ulcers in pediatric intensive care: incidence and factors. Ped Crit Care Med 2003;4:284-384.
11. Chen Y, Devivo MJ, Mackson AB. Pressure ulcer prevalence in people with spinal cord injury: age-period-duration effects. Arch Phys Med Rehabil 2005;86:1208-13.
12. McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil 1999;80:1402-10.
13. Beckrich K, Aronovitch SA. Hospital-acquired pressure ulcers: a comparison of costs in medical vs. surgical patients. Nurs Econ 1999;17:263-71.
14. Kantor J, Margolis DJ. Expected healing rates for chronic wounds. Wounds 2000;12:155-8.
15. Pham HT, Economides PA, Veves A. The role of endothelial function on the foot: microcirculation and wound healing in patients with diabetes. Clin Podiatr Med Surg 1998;15:85-93.
16. Buillot B, Dandurand M, Guilhou JJ. Skin perfusion pressure in leg ulcers assessed by photoplethysmography. Int Angiol 1988;7:33-4.
17. Schubert V, Perbeck L, Schubert PA. Skin microcirculatory and thermal changes in elderly subjects with early stage of pressure sores. Clin Physiol 1994;14:1-13.
18. OTR3 Chronic wound healing kit CACIPLIQ20® RGTA®: The matrix therapy for regeneration. [accessed on 15 December 2009].
19. Barritault D, Caruelle JP. Regenerating agents (RGTAs): a new therapeutic approach. Ann Pharm Fr 2006;64:135-44. Review. French.
20. Garcia-Filipe S, Barbier-Chassefiere V, Alexakis C, Huet C, Ledoux D, Kerros ME, Petit E, Barritault D, Caruelle JP, Kern P. RGTA OTR41 20, a heparan sulfate mimetic is a possible long-term active agent to heal burned skin. J Bio Mater Res 2007;75-84.
21. Tong M, Zbinden MM, Hekking IJ, Vermeij M, Barritault D, Van Neck JW. RGTA OTR 4120, a heparan sulphate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds. Wound Repair Regen 2008;16:294-9.
22. Mangoni M, Yue XL, Morin C, Violot D, Frascogna V, Tao YG, Caruelle JP, Huang QF, Li P, Barritault D, Biti G, Bourhis J. An heparan-mimetic of the RGTA family protects mice from radiation-induced mucositis. Int J Radiation Oncology Biol Phys 2009;74:1242-50.
23. Barbier-Chassefière V, Garcia-Filipe S, Yue Xl, Kerros Me, Petit E, Kern P, Saffar Jl, Papy-Garcia D, Caruelle JP, Barritault D. Matrix therapy and regenerative medicine, a new approach for chronic wound healing. J Bio Mater Res A 2009;90:641-7.
24. Tong M, Tuk B, Hekking IM, Vermeij M, Barritault D, van Neck JW. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen 2009;17:840-52.
25. deGouveia Santos VL, Sellmer D, Massulo MM. Inter-rater reliability of Pressure Ulcer Scale for Healing (PUSH) in patients with chronic leg ulcers. Rev Lat Am Enfermagem 2007;15:391-6.
26. Ratliff CR, Rodeheaver GT. Use of the PUSH tool to measure venous ulcer healing. Ostomy Wound Manage 2005;51:58-60.
27. George-Saintilus E, Tommasulo B, Cal CE, Hussain R, Mathew N, Dlugacz Y, Pekmezaris R, Wolf-Klein G. Pressure ulcer PUSH score and traditional nursing assessment in nursing home residents: do they correlate?. J Am Med Dir Assoc 2009; 10:141-4. Epub 8 January 2009.
28. de Laat EH, Scholte op Reimer WJ, van Achterberg T. Pressure ulcers: diagnostics and interventions aimed at wound-related complaints: a review of the literature. J Clin Nurs 2005;14:464-72.
29. Hollinworth H. The management of patients' pain in wound care. Nurs Stand 2005;20:65-6, 68, 70 passim.
30. Panuncialman J, Falanqa V. The science of wound be preparation. Surg Clin North Am 2009;89:611-26.
31. Schultz GS, Ladwig G, Wysocki A. Extracellular matrix: review of its roles in acute and chronic wounds. World Wide Wounds 2005 [accessed 1 November 2010].
32. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996;4:411-20.
33. Clark RA. Fibrin and wound healing. Ann N Y Acad Sci 2001;936:355-67.
34. Haraway GD. The extracellular matrix in wound healing. Healthpoint Communications. [accessed 1 November 2010].
35. Schultz GS, Wysocki A. Interactiona between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009;17:153-62.
36. Agren MS, Werthen M. The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Lower Extrem Wounds. 2007;6:82-97.
37. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002;137:822-7.
38. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002;10:16-25.
39. Vieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blinc study. Diabetes Care 1998;21:822-7.
40. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis. Diabetes Care 1999;22:692-5.
41. Solomon DE. An in vitro examination of an extracellular matrix scaffold for use in wound healing. Int J Exp Pathol 2002;83:209-16.
42. Vlodavshy I, Friedman Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-7.
43. ® The matrix therapy for regeneration. 2009: [accessed on 15 December 2009].
44. Khammari-Chebbi CK, Kichenin K, Amar N, Nourry H, Warnet JM, Barritault D, Baudouin C. Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol 2008;31:465-71.
45. Agren MS, Werthén M. The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Int J Low Extrem Wounds 2007;6:82-97.
46. Hodde JP, Johnson CE. Extracellular matrix as a strategy for treating chronic wounds. Am J Clin Dermatol 2007;8:61-6.
47. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 1999;13:761-6.
48. Yamauchi H, Desgranges P, Lecerf L, Papy-Garcia D, Tournaire MC, Moczar M, Loisance D, Barritault D. New agents for the treatment of infarcted myocardium. FASEB J 2000;14:2133-4.
49. Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem 2005;280:32792-800.
50. Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot MA, Barritault D, Caruelle JP, Kern P. Structurally different RGTAs modulate collagen-type expression by cultured aortic smoot muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-1. The FASEB j-FJ Express 2008; Available at: [accessed 1 April 2008].
51. Rudolph R, Suzuki M, Luce JK. Experimental skin necrosis produced by adriamycin. Cancer Treat Rep 1979;63:529-37.
52. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, IIan N, Vlodavsky I, Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005;19:211-21.
53. Barritault D, Allaire E, Louissaint T, Kichenin K, Godeau B, Becquemin JP, Desgranges P. Matrix therapy in vascular pathology: first pilot study to evaluate RGTA Cacipliq 20. Abstract at Toronto 2nd World Union of Wound Healing Society meeting; 2008 June 2-4 [accessed on 1 November 2010].
54. Walker MJ. A comparative study of the use of exsikines and other advanced wound care products/modalities in the treatment of various wound types in efficacy. Adv Skin Wound Care 2008;21:218-26.
55. Newman MI, Baratta LG, Swartz K. Activated, Type I collagen (CellerateRx) and its effectiveness in healing recalcitrant diabetic wounds: a case presentation. Adv Skin Wound Care 2008;21:370-4.
56. Braakenburg A, Obdeign MC, Feitz R, van Rooij I, van Griethuysen AJ, Klinkenbijl J. The clinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the management of acute and chronic wounds: a randomized controlled trial. J Plas Reconstr Surg 2006;118:390-7.
57. Moues CM, van den Bemd GJCM, Heule F, Hovius SER. Comparing conventional gauze therapy to vacuum-assisted closure wound therapy: a prospective randomized trial. J Plas Reconstruc Aesth Surg 2007;60:672-81.
58. Cardenas DD, Hoffman JM, Kirshblum S, McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch Phys Med Rehabil 2004;85:1757-63.
59. Kranke P, Bennett MH, Debus SE, Roeckl-Wiedmann I, Schnabel A. Hyperbaric oxygentherapy for chronic wounds. Cochrane Database Syst Rev 2004; Issue 1. Art. No.: CD004123. DOI: 10.1002/14651858.CD004123.pub2..
60. De la Torre JI, Chambers JA. Wound healing, chronic wounds. October 9, 2008 [accessed 21 May 2009].
61. Moretti B, Notarnicola A, Maggio G, Moretti L, Pascone M, Tafuri S, Patella V. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. BMC Musculoskelet Disord 10:54.
62. Attinger CE, Janis FE, Steinberg J, Schwartz J, Al-Attar A, Couch K. Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg 2006;117:72S-109S.
63. Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 2001;135:773.
64. Woo KY, Sibbald RG. Chronic wound pain: a conceptual model. Adv Skin Wound Care 21:175-88.
65. Ashfield T. The use of topical opioids to relieve pressure ulcer pain. Nurs Stand 2005;19:90-2.
66. Flock P. Pilot study to determine the effectiveness of diamorphine gel to control pressure ulcer pain. J Pain Symptom Manage 2003;25:547-54.
67. Langemo D, Thompson P, Hanson D, Anderson J, Hunter S. Topical anesthesia for pressure ulcer treatment. Adv Skin Wound Care 2008;21:364-9.
68. Zeppetella G, Paul J, Ribeiro MD. Analgesic efficacy of morphine applied topically to painful ulcers. J Pain Symptom Manage 2003;25:555-8.
69. Thomas DR. Prevention and treatment of pressure ulcers: what works? what doesn't?. Cleve Clin J Med 2001;68:704-7, 710-14, 717-22.
70. Briggs M, Nelson EA. Topical agents or dressings for pain in venous leg ulcers. Cochrane Database Syst Rev 2003;(1):CD001177. DOI: 10.1002/14651858.CD001177..
71. Douglas V. Living with a chronic leg ulcer: an insight into patients' experiences and feelings. J Wound Care 2001;10:355-60.
72. Keast DH, Parslow N, Houghton PE, Norton L, Fraser C. Best practice recommendations for the prevention and treatment of pressure ulcers: update 2006. Adv Skin Wound Care 2007;20:447-60. quiz 461-2